{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"groups":[{"description":"* Rituximab 375 mg/m2 IV day1\n* Cladribine 4 mg/m2 IV over 2 hours days 1-5\n* Bortezomib 1.3 mg/m2 IV days 1 and 4\n* Repeat every 28 days for a maximum of 6 cycles\n\nrituximab: 375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.\n\nbortezomib: 1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.\n\ncladribine: 4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.","id":"OG000","title":"VCR (Velcade, Cladribine and Rituximab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Two years","title":"Partial Response","type":"SECONDARY","unitOfMeasure":"Participants"}